Triple Transgenic Model of Alzheimer's Disease
Triple Transgenic Model of Alzheimer's Disease
批准号:
6896185
负责人:
MICHAEL PETER VITEK
金额:
$37.03万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-06-15 至 2007-05-31
关键词:
Alzheimer&aposs diseaseamyloid proteinsapolipoprotein Ebiological modelsbiotechnologydementiadisease /disorder modelgene targetinggenetically modified animalshistochemistry /cytochemistryhuman genetic material taglaboratory mousemodel design /developmentmonoclonal antibodyneural degenerationneuritic plaquesneurofibrillary tanglesneuroimagingneuropathologytau proteinstissue /cell preparation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from applicant's abstract): The National Institutes on
Aging and Reagan Institute consensus criteria for the diagnosis of Alzheimer's
disease includes a clinical evaluation of progressive dementia and a
post-mortem observation of both amyloid plaques and neurofibrillary tangles in
the brains of AD patients. Age of the patient is the largest risk for the
presence of AD followed by the presence of one or more epsilon-4 alleles of the
apolipoprotein-E gene (APOE4) in about 45 percent of all AD patients. The
presence of APOE4 is also associated with an increase in the numbers of
neurofibrillary tangles and amyloid plaques compared to those AD patients that
lack APOE4 alleles. These data imply that increased numbers of plaques and
tangles are associated with a gain of Alzheimer's dementia.
An animal model that displays progressive dementia, amyloid plaques and
neurofibrillary tangles is a critical step forward toward developing a safe and
effective drug for the treatment of Alzheimer's disease. Based on reported
studies of AD patients, an animal model should also display increased numbers
of neurofibrillary tangles and amyloid plaques when APOE4 gene products are
present.
We propose to make a mouse model of Alzheimer's disease to meet the National
Institute of Aging-Reagan Institute criteria for Alzheimer's disease. This
triple transgenic mouse (APP + TAU + APOE) is designed to display both
neurofibrilary tangles and amyloid plaques in their brains. To be an accurate
model of human AD, we hypothesize that the numbers of neurofibrillary tangles
and amyloid plaques should increase in the presence of human APOE4 gene
products compared to human APOE3 gene products. Although work on plaque-only or
tangle-only mice needs to continue, if we are really going to develop a mouse
model of Alzheimer's disease, we must have progressive dementia, plaques, and
tangles. Such a model would facilitate exploration of the basic mechanisms that
cause neurodegeneration and dementia, in the 'presence of plaques, tangles and
apoE proteins, and thus, greatly facilitate the finding of a safe and effective
drug to block Alzheimer's dementia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DFMO Therapy for Polycystic Kidney Disease
-
批准号:10080836
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2020
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Novel Orally-Available Prodrugs for Alzheimer's Disease
-
批准号:8979556
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Inhibitor #2 of Protein Phosphatase 2A (I2PP2A) and Asthma
-
批准号:8644994
-
项目类别:
-
资助金额:$26.82万
-
财政年份:2014
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Investigational Safety and Toxicity Studies of Subcutaneous COG1410 for Alzheimer
-
批准号:8583226
-
项目类别:
-
资助金额:$27.32万
-
财政年份:2013
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Novel COG Compounds to Treat Asthma
-
批准号:8314407
-
项目类别:
-
资助金额:$26.18万
-
财政年份:2012
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Small Molecule Screen for Apolipoprotein-E/Alzheimer's Disease
-
批准号:8310950
-
项目类别:
-
资助金额:$29.05万
-
财政年份:2010
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Small Molecule Screen for Apolipoprotein-E/Alzheimer's Disease
-
批准号:8142915
-
项目类别:
-
资助金额:$22.58万
-
财政年份:2010
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Small Molecule Screen for Apolipoprotein-E/Alzheimer's Disease
-
批准号:7947726
-
项目类别:
-
资助金额:$43.31万
-
财政年份:2010
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Novel Intervention for Colitis
-
批准号:7218881
-
项目类别:
-
资助金额:$27.93万
-
财政年份:2007
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Novel Intervention for Amyloid-Induced Neuroinflammation
-
批准号:7269009
-
项目类别:
-
资助金额:$26.34万
-
财政年份:2007
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Novel Immunological Modifer as a Tissue Protector
-
批准号:7154922
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2006
-
负责人:MICHAEL PETER VITEK
-
依托单位:
NOVEL INHIBITORS OF BRAIN ISCHEMIA
-
批准号:6694156
-
项目类别:
-
资助金额:$28.4万
-
财政年份:2003
-
负责人:MICHAEL PETER VITEK
-
依托单位:
NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS
-
批准号:7125177
-
项目类别:
-
资助金额:$69.27万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS
-
批准号:7276561
-
项目类别:
-
资助金额:$34.61万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Triple Transgenic Model of Alzheimer's Disease
-
批准号:7059417
-
项目类别:
-
资助金额:$36.16万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Triple Transgenic Model of Alzheimer's Disease
-
批准号:6477800
-
项目类别:
-
资助金额:$36.77万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Neuroprotective Apolipoprotein-E Analogs Continuation
-
批准号:7481429
-
项目类别:
-
资助金额:$106.69万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Neuroprotective Apolipoprotein-E Analogs Continuation
-
批准号:7683769
-
项目类别:
-
资助金额:$105.65万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS
-
批准号:6444843
-
项目类别:
-
资助金额:$20.18万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
Triple Transgenic Model of Alzheimer's Disease
-
批准号:6753483
-
项目类别:
-
资助金额:$37.03万
-
财政年份:2002
-
负责人:MICHAEL PETER VITEK
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: